Ons wil graag hê dat jy deel word van ons gemeenskap. Sluit aan by ons Discord om met ons en ander lede te skakel!

Ticker
IBAB.BR

Price
13.30
Stock movement up
+0.20 (1.53%)
Company name
Ion Beam Applications SA
Exchange
(BR
,
Currency
EUR
)
Sector
Healthcare >
Medical Devices
Markkapitalisasie
388.11M
Ondernemingswaarde
833.80M
Prys/Verkope
0.61
Prys/Boek
4.30
Dividendopbrengs
-
Dividendgroei
-
Groei jare
-
FCF uitbetaling
-8.99%
Agterlopende P/E
-
Volgende P/E
12.67
PEG
-
EPS groei
15.97%
1 jaar opbrengs
15.25%
3 jaar opbrengs
-3.54%
5 jaar opbrengs
6.41%
10 jaar opbrengs
-3.28%
Laaste opgedateer: 2024-12-21

DIVIDENDE

IBAB.BR betaal nie dividende nie of geen data is ontvang nie

WAARDERING

Waarderingsverhoudings

Loading...
Waarderingsverhoudings gegewens
Agterlopende P/E-
Prys tot OCF-
Prys tot FCF-
Prys tot EBITDA29.93
EV tot EBITDA64.30

Waardering (Verkope/Boekwaarde)

Loading...
Waardering (Verkope/Boekwaarde) gegewens
Prys tot verkope0.61
Prys tot Boekwaarde4.30
EV tot verkope1.31

FINANSIËLE

Per aandeel

Loading...
Per aandeel gegewens
Huidige aandeeltelling29.18M
EPS (TTM)-0.67
FCF per aandeel (TTM)-3.68

Inkomstestaat

Loading...
Inkomstestaat gegewens
Inkomste (TTM)635.17M
Bruto wins (TTM)204.27M
Bedryfsinkomste (TTM)3.46M
Netto inkomste (TTM)-19.41M
EPS (TTM)-0.67
EPS (1j vorentoe)1.05

Marges

Loading...
Marges gegewens
Bruto marge (TTM)32.16%
Bedryfsmarge (TTM)0.54%
Winsgrens (TTM)-3.06%

Balansstaat

Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Balansstaat gegewens
Kontant60.19M
Netto debiteure165.72M
Totale bedryfsbates449.19M
Klandisiewaarde11.45M
Ontasbare bates14.12M
Eiendom, aanleg en toerusting0.00
Totale bates596.16M
Rekeninge betaalbaar66.24M
Kort/huidige langtermynskuld59.98M
Totale bedryfslaste467.11M
Totale laste505.87M
Aandeelhouersbelang90.28M
Netto tasbare bates0.00

Kontantvloei

Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Kontantvloei gegewens
Bedryfskontantvloei (TTM)-91.43M
Kapitale uitgawes (TTM)15.86M
Vrye kontantvloei (TTM)-107.29M
Dividende betaal (TTM)9.64M

Finansiële opbrengste

Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Finansiële opbrengste gegewens
Opbrengs op ekwiteit-21.50%
Opbrengs op bates-3.26%
Opbrengs op belegde kapitaal-16.02%
Kontant opbrengs op belegde kapitaal-88.53%

AANDELE INLIGTING

Aandele grafiek

Loading...
Aandele prys data
Open13.08
Daaglikse hoog13.38
Daaglikse laag13.00
Daaglikse volume37K
Hoogtepunt van alle tye64.49
1j analiseraaming17.97
Beta0.99
EPS (TTM)-0.67
Dividend per aandeel-
Ex-dividend datum19 Jun 2024
Volgende verdienste datum19 Mar 2025

Afwaartse potensiaal

Loading...
Afwaartse potensiaal gegewens
IBAB.BRS&P500
Huidige prysdaling vanaf die hoogste punt van alle tye-79.38%-2.74%
Hoogste prysdaling-95.97%-56.47%
Datum van hoogste daling28 Mar 20039 Mar 2009
Gemiddelde daling vanaf hoogtepunt-72.91%-11.13%
Gemiddelde tyd tot nuwe hoogtepunt322 days12 days
Maksimum tyd tot nuwe hoogtepunt6557 days1805 days
MAATSKAPPY BESONDERHEDE
IBAB.BR (Ion Beam Applications SA) company logo
Markkapitalisasie
388.11M
Markkapitalisasie kategorie
Small-cap
Beskrywing
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Werknemers
1943
Beleggerverhoudings
-
CEO
Land
Belgium
Stad
Aandele tipe
-
CCC status
-
Dividendfrekwensie
-
GEBEURE EN AANBIEDINGS
GebeureAanbiedings
Loading...
VERSTAAN DIE BESIGHEID
Loading...
MAATSKAPPY NUUS
Alle nuusPersvrystellings
NOTICE OF A GENERAL MEETING OF IBA SA 7 January 2025 at 10 a.m. Dear Shareholder, We have the honour of convening you to a General Meeting of IBA (the "GM") at the Company's [registered office] on 7 J...
6 Desember 2024
Louvain-la-Neuve, Belgium, 5 December 2024 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, announces today an initiative aimed at perpetuating the entrepreneuria...
5 Desember 2024
Louvain-la-Neuve, Belgium, 21 November 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 ...
21 November 2024
Fourth agreement secured by IBA Industrial Solutions in past six weeks Louvain-la-Neuve, Belgium, November 06, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technolo...
6 November 2024
A EUR 16 million Initiative to Establish Strategic EU Autonomy in Alpha Therapies for Cancer Louvain-la-Neuve, Belgium, October 3, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader i...
3 Oktober 2024
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, October 1st, 2024 06:00 Summary of the notification IBA (Ion Beam Applications), the w...
1 Oktober 2024
Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture...
11 September 2024
GROUP REVENUES UP 21.9% ACCELERATED BACKLOG CONVERSION IN PROTON THERAPY AND OTHER ACCELERATORS STRONG GROSS MARGIN IMPROVEMENT AND BREAKEVEN REBIT Louvain-la-Neuve, Belgium, 29 August 2024 - IBA (Ion...
29 Augustus 2024
Agreement further strengthens the long-term relationship between IBA and the University of Pennsylvania Louvain-La-Neuve, Belgium, August 27, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the wor...
27 Augustus 2024
HY24 results webcast to take place on Thursday, 29 August 2024 at 3pm CEST Louvain-la-Neuve, Belgium, 1 August 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerat...
1 Augustus 2024
Volgende bladsy